- Home
- GECC vs RAPT Comparison
GECC vs RAPT Comparison
Compare GECC & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GECC
- RAPT
- Stock Information
- Founded
- GECC 2016
- RAPT 2015
- Country
- GECC United States
- RAPT United States
- Employees
- GECC N/A
- RAPT N/A
- Industry
- GECC Finance: Consumer Services
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- GECC Finance
- RAPT Health Care
- Exchange
- GECC Nasdaq
- RAPT Nasdaq
- Market Cap
- GECC 123.1M
- RAPT 122.9M
- IPO Year
- GECC N/A
- RAPT 2019
- Fundamental
- Price
- GECC $11.00
- RAPT $11.53
- Analyst Decision
- GECC
- RAPT Buy
- Analyst Count
- GECC 0
- RAPT 5
- Target Price
- GECC N/A
- RAPT $36.75
- AVG Volume (30 Days)
- GECC 27.6K
- RAPT 105.6K
- Earning Date
- GECC 08-04-2025
- RAPT 08-07-2025
- Dividend Yield
- GECC 13.91%
- RAPT N/A
- EPS Growth
- GECC N/A
- RAPT N/A
- EPS
- GECC 0.42
- RAPT N/A
- Revenue
- GECC $42,909,000.00
- RAPT N/A
- Revenue This Year
- GECC $32.09
- RAPT N/A
- Revenue Next Year
- GECC $0.51
- RAPT N/A
- P/E Ratio
- GECC $26.03
- RAPT N/A
- Revenue Growth
- GECC 18.13
- RAPT N/A
- 52 Week Low
- GECC $8.87
- RAPT $5.67
- 52 Week High
- GECC $11.39
- RAPT $27.84
- Technical
- Relative Strength Index (RSI)
- GECC 57.62
- RAPT 56.60
- Support Level
- GECC $10.94
- RAPT $12.14
- Resistance Level
- GECC $11.03
- RAPT $13.50
- Average True Range (ATR)
- GECC 0.09
- RAPT 1.13
- MACD
- GECC -0.01
- RAPT 0.19
- Stochastic Oscillator
- GECC 90.91
- RAPT 56.39
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.